Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension

Journal of the American Society of Hypertension

Volumn 2, Issue 6, 2008, Pages 462-468

  Calhoun, David A ^a   White, William B ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Ambulatory blood pressure; antihypertensive agents; glomerular filtration rate; serum aldosterone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LOOP DIURETIC AGENT; POTASSIUM; RENIN; THIAZIDE DIURETIC AGENT;

ADULT; AGE; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; OPEN STUDY; PATIENT COMPLIANCE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RACE; SYSTOLIC BLOOD PRESSURE; THERAPY RESISTANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 57149110441     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.05.005     Document Type: Article

References (26)

1. Calhoun D.A. Resistant or difficult-to-treat hypertension. J Clin Hypertens 8 (2006) 181-186
2. Moser M., and Setaro J. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 355 (2006) 385-392
3. Epstein M., and Calhoun D.A. The role of aldosterone in resistant hypertension: implications for pathogenesis and treatment. Curr Hypertens Rep 9 (2007) 98-105
4. Mansoor G.A., and White W.B. Circadian blood pressure variation in hypertensive patients with primary hyperaldosteronism. Hypertension 31 (1998) 843-847
5. Rose L.I., Underwood R.H., Newmark S.R., Kisch E.S., and Williams G.H. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 87 (1977) 398-403
6. Lee T.H. Spironolactone and gynecomastia. Harvard Heart Lett 14 (2003) 3
7. De Gasparo M., Joss U., Ramjoue H.P., Whitebread S.E., Haenni H., Schenkel L., et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240 (1987) 650-656
8. White W.B., Carr A.A., Krause S., Jordan R., Roniker B., and Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92 (2003) 38-42
9. White W.B., Duprez D., St Hillaire R., Krause S., Roniker B., Kuse-Hamilton J., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (2003) 1021-1026
10. Krum H., Nolly H., Workman D., He W., Roniker B., Krause S., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 (2002) 117-123
11. Weinberger M.H., White W.B., Ruilope L.M., MacDonald T.M., Davidson R.C., Roniker B., et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 150 (2005) 426-433
12. Flack J.M., Oparil S., Pratt J.H., Roniker B., Garthwaite S., Kleiman J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 41 (2003) 1156-1158
13. White W.B., Viadero J.J., Lane T.J., and Podesla S. Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 39 (1986) 43-48
14. White W.B. Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. J Clin Hypertens 9 (2007) 25-30
15. White W.B., Giles T.G., Bakris G.L., Neutel J., Davidai G., and Weber M.A. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J 151 (2006) 176-184
16. Cockcroft D., and Gault M.D. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
17. Goodwin J., Bilous M., Winship S., Finn P., and Jones S.C. Validation of the Oscar 2 oscillometric 24-hour ambulatory blood pressure monitor according to the British Hypertension Society protocol. Blood Press Monit 12 (2007) 113-117
18. White W.B., Mehotra D., Black H.R., and Fakouhi T.D. Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group. Am J Cardiol 80 (1997) 469-474
19. Black H.R., Bakris G.L., Weber M.A., Weiss R., Shahawy M.E., Marple R., et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens 9 (2007) 760-769
20. Ouzan J., Perault C., Lincoff A.M., Carre E., and Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15 (2002) 333-339
21. Nishizaka M., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
22. Chapman N., Dobson J., Wilson S., Dahlof B., Sever P.S., Wedel H., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
23. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 217 (2004) 45-52
24. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R., Roniker B., et al. Effects of eplerenone, enalapril, and eplerenone and enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
25. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
26. Lane D.A., and Beevers D.G. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin receptor blocking agent. J Hypertens 25 (2007) 2515-2516